Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) dropped 3.5% during mid-day trading on Thursday . The company traded as low as $5.75 and last traded at $5.85, with a volume of 1,866,732 shares. The stock had previously closed at $6.06.

PGNX has been the topic of several recent analyst reports. Brean Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Tuesday, April 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Progenics Pharmaceuticals in a report on Monday, April 4th. Jefferies Group reaffirmed a “buy” rating and set a $9.00 price objective on shares of Progenics Pharmaceuticals in a report on Wednesday, April 6th. Zacks Investment Research downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Progenics Pharmaceuticals in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.95.

The firm’s market cap is $409.18 million. The firm has a 50-day moving average of $5.05 and a 200-day moving average of $4.73.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $3.27 million. Progenics Pharmaceuticals’s revenue for the quarter was up 908.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.15) earnings per share. On average, analysts anticipate that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.